Experimental drug TURALIO takes on tough childhood cancers

NCT ID NCT02390752

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study is testing a drug called TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has come back or not responded to standard treatments. The cancers include certain leukemias, solid tumors, and tumors linked to neurofibromatosis type 1. The goal is to find the safest dose and see if the drug can shrink tumors or stop them from growing. Participants take the drug daily for up to 2 years and are closely monitored with tests and scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.